Candela Ignites European Aesthetics Market with Triple-Threat Tech Launch

PARIS, FRANCE – January 30, 2026 – Global aesthetic technology leader Candela has made a significant strategic move in the European market, unveiling a trio of advanced skin treatment systems at the prestigious IMCAS World Congress 2026. The European launch of the new Glacē™ facial treatment platform, alongside the showcase of its next-generation Matrix™ radiofrequency system and the Vbeam® Pro vascular laser, signals an aggressive expansion aimed at capturing a larger share of the continent's rapidly growing aesthetics industry.

This multi-platform launch is more than a product release; it represents a calculated push to redefine comprehensive skin health treatment, backed by a deep-rooted commitment to clinical validation that the company hopes will set it apart in a crowded field.

A Strategic Play in a Booming Market

Candela's timing is impeccable. The European medical aesthetic devices market is on a steep growth trajectory, projected to climb from USD 8.17 billion in 2025 to over USD 14 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.65%. This surge is fueled by a confluence of factors, including Europe's aging demographic seeking to maintain a youthful appearance and a strong consumer preference for minimally invasive procedures, which accounted for over half of the market in 2025.

Energy-based platforms, Candela's specialty, remain the cornerstone of this market, commanding a 52% share. By introducing three distinct yet complementary systems, the company is positioning itself to meet a wide spectrum of patient demands. “By launching these major platforms, we are accelerating our ability to serve customers in the fast-evolving European and global market, where patient demand continues to grow,” said Geoffrey Crouse, Chief Executive Officer of Candela.

The strategy appears to be one of integration. The Glacē system targets the burgeoning high-frequency skincare segment, the Matrix system addresses the dominant radiofrequency (RF) skin renewal market—a segment that held a 44.7% revenue share in 2025—and the Vbeam Pro enhances capabilities in the specialized vascular laser field. This comprehensive approach allows aesthetic practices, from medical clinics to wellness centers, to build an entire treatment ecosystem around Candela's technology.

The Technology Behind the Transformation

At the heart of Candela's announcement are the technological advancements designed to deliver superior and more consistent patient outcomes. Each system brings a unique set of capabilities to the practitioner's toolkit.

The Glacē System is a comprehensive skin purifying and hydrating platform. Inspired by the 'glass skin' trend, it functions as a versatile professional facial treatment. It can be used as a standalone service for high-frequency skincare or, critically, as a preparatory and adjunctive treatment to improve the results and comfort of energy-based device procedures. Its multi-modal approach includes hydrodermabrasion, dual-mode cupping massage for lymphatic drainage, and LED light therapy. Clinical trials have already demonstrated impressive results, with 100% of subjects reporting visibly cleaner skin and 97% experiencing improved hydration.

The Matrix System, currently pending EU MDR clearance, is a next-generation, multi-application RF workstation. It combines skin resurfacing, microneedling, and non-invasive wrinkle treatments in a single device. Its standout feature is Candela's proprietary Aesthetic Intelligence technology, which senses and adapts to tissue impedance in real-time. This intelligent feedback loop is designed to ensure safe, consistent heating across different skin types and treatment depths, leading to more reproducible outcomes for conditions like skin laxity, acne scarring, and textural irregularities. The system has already gained traction in the U.S., where its RF microneedling applicator received FDA 510(k) clearance in 2024 for treating facial wrinkles.

Finally, the Vbeam Pro System builds on Candela's iconic vascular laser legacy. It combines an advanced 595 nm pulsed dye laser (PDL) with a 1064 nm Nd:YAG wavelength, offering practitioners unmatched versatility. The platform is engineered to treat an extensive list of conditions, from rosacea and port-wine stains to acne, scars, and wrinkles. Its most significant distinction is being the only vascular laser with FDA clearance for use in pediatric patients, a testament to its established safety profile and precision.

Navigating a Competitive and Regulated Landscape

Candela is not entering an empty arena. The European aesthetic device market is fiercely competitive, with established players like Alma Lasers, Venus Concept, and Cynosure all vying for market leadership. For instance, Alma Lasers recently won accolades for its Harmony platform, while Venus Concept gained CE-Mark approval for its Venus Versa Pro system in 2024.

To stand out, Candela is leveraging its integrated approach and deep scientific roots. The pending EU MDR clearance for the Matrix system highlights a critical hurdle for all manufacturers. The European Union's Medical Device Regulation has instituted stricter requirements for clinical evidence and post-market surveillance, raising the bar for entry. While this presents a temporary delay for the Matrix system's full European rollout, successfully navigating this rigorous process can become a competitive advantage, signaling a high standard of safety and efficacy to practitioners and patients.

A Foundation of Science and Clinical Validation

In an industry where marketing claims can often outpace scientific proof, Candela is anchoring its strategy in a foundation of clinical evidence. The company frequently points to its legacy of over 3,000 peer-reviewed and published articles and its current portfolio of 32 ongoing global clinical studies. This commitment to research is a key differentiator.

The Vbeam Pro's unique FDA clearance for pediatric use and the Matrix system's 2025 Cosmopolitan Acne Award, which was based on evaluations by dermatologists, provide third-party validation of the technology's effectiveness. The strategy of creating systems that work in concert is also resonating with top-tier practitioners.

“As someone whose practices use both the Glacē and Matrix systems, I see these platforms as highly complementary,” noted Dr. Firas Al-Niaimi, a London-based dermatologist. “Together, they allow us to comprehensively address skin health — including skin laxity, texture and tone — safely with precision and confidence.”

This sentiment aligns with broader industry trends, where surveys show a strong preference among physicians for multi-application devices that offer treatment versatility and a wider patient reach. By showcasing this new trifecta of technologies at IMCAS, Candela is not just launching products; it is presenting a vision for the future of aesthetic practice—one that is integrated, technologically advanced, and, above all, clinically proven. The company's efforts at the congress, including a dedicated symposium on epigenetics and immersive brand experiences, further underscore its intent to lead through science and partnership.